Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
23.86
+0.73 (3.16%)
Dec 20, 2024, 4:00 PM EST - Market closed
Spyre Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Spyre Therapeutics stock have an average target of 51.5, with a low estimate of 40 and a high estimate of 65. The average target predicts an increase of 115.84% from the current stock price of 23.86.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 13, 2024.
Analyst Ratings
The average analyst rating for SYRE stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 4 | 4 | 3 |
| Buy | 4 | 4 | 5 | 5 | 5 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 8 | 9 | 9 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jones Trading | Jones Trading | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Dec 11, 2024 |
| Baird | Baird | Buy Maintains $50 → $65 | Buy | Maintains | $50 → $65 | +172.42% | Nov 13, 2024 |
| Guggenheim | Guggenheim | Strong Buy Maintains $50 → $65 | Strong Buy | Maintains | $50 → $65 | +172.42% | Oct 25, 2024 |
| Wedbush | Wedbush | Buy Initiates $45 | Buy | Initiates | $45 | +88.60% | Sep 4, 2024 |
| Evercore ISI Group | Evercore ISI Group | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Jul 16, 2024 |
Financial Forecast
Revenue This Year
2.38M
from 886.00K
Increased by 168.62%
Revenue Next Year
3.51M
from 2.38M
Increased by 47.61%
EPS This Year
-4.51
from -49.12
EPS Next Year
-4.23
from -4.51
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 21.0M | 31.5M | 1.1M | |||
| Avg | 2.4M | 3.5M | 145,717 | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 2,270.2% | 1,223.5% | -70.1% | |||
| Avg | 168.6% | 47.6% | -95.9% | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -4.17 | -3.31 | -2.97 | |||
| Avg | -4.51 | -4.23 | -4.66 | |||
| Low | -4.64 | -4.76 | -6.00 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.